Company: INTS
Filing Date: 2025-03-28
Form Type: DRS
Source: 0001628279-25-000170
Chunk: 17

Company: INTENSITY THERAPEUTICS, INC.
Filing Date: 2025-03-28
Form: DRS
Chunk 17
---
 deciding to invest in shares of the Common Stock.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Nasdaq Capital Market Symbol |     | INTS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |

Except as otherwise indicated, the number of shares of Common Stock to be outstanding immediately after this offering is based on 15,264,869 shares of our Common Stock outstanding as of March 28, 2025 and excludes, as of such date, the following: • 2,543,066 shares of Common Stock issuable upon the exercise of outstanding stock options with a weighted average exercise price of $6.18 per share; • 2,041,563 shares of Common Stock issuable upon the exercise of outstanding warrants to purchase Common Stock with a weighted average exercise price of $4.32 per share; and • 2,455,012 additional shares of the Common Stock reserved for future issuance under our equity incentive plans. Unless otherwise indicated, the discussion and table above assume no exercise of the outstanding options and warrants described above and excludes the shares of Common Stock to be issued upon exercise of the Common Warrants and Pre-Funded Warrants offered in this offering.

<div align='center'>7

Confidential Treatment Requested by Intensity Therapeutics, Inc.</div>

#### Pursuant to 17 C.F.R. Section 200.83

### RISK FACTORS
Investing in our securities involves a high degree of risk. You should carefully consider and evaluate all of the information contained in this prospectus and in the documents we incorporate by reference into this prospectus before you decide to purchase our securities. In particular, you should carefully consider and evaluate the risks and uncertainties described under the heading “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2024. Any of the risks and uncertainties set forth below and in the Annual Report, as updated by annual, quarterly and other reports and documents that we file with the SEC and incorporate by reference into this prospectus, or any prospectus, could materially and adversely affect our business, results of operations and financial condition, which in turn could materially and adversely affect the value of any securities offered by this prospectus. As a result, you could lose all or part of your investment .

#### Risks Related to this Offering
This is a reasonable best efforts offering, with no minimum amount of securities required to be sold, and we may sell fewer than all of the securities offered hereby.

The Placement Agents have agreed to use their reasonable best efforts to solicit offers